Joseph Catanzaro
Stock Analyst at Mizuho Securities
(4.46)
# 1,094
Out of 4,417 analysts
433
Total ratings
44.7%
Success rate
10.5%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Reiterated: Buy | $30 → $36 | $32.16 | +11.94% | 8 | Jun 8, 2026 | |
| QTTB Q32 Bio | Initiated Coverage: Buy | $14 | $12.75 | +9.80% | 1 | May 22, 2026 | |
| AVTX Avalo Therapeutics | Maintained: Buy | $39 → $45 | $14.33 | +214.03% | 3 | May 14, 2026 | |
| UPB Upstream Bio | Maintained: Buy | $51 → $50 | $5.92 | +744.59% | 2 | May 14, 2026 | |
| ERAS Erasca | Maintained: Buy | $28 → $26 | $13.38 | +94.32% | 4 | May 12, 2026 | |
| STRO Sutro Biopharma | Initiated Coverage: Buy | $50 | $28.17 | +77.49% | 1 | Apr 30, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $140 → $185 | $156.58 | +18.15% | 15 | Apr 24, 2026 | |
| CLYM Climb Bio | Initiated Coverage: Buy | $18 | $10.71 | +68.07% | 1 | Apr 15, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $53 → $84 | $83.41 | +0.71% | 3 | Apr 14, 2026 | |
| APGE Apogee Therapeutics | Maintained: Buy | $105 → $110 | $85.24 | +29.05% | 8 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 | $9.07 | +186.66% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $17.07 | +75.75% | 26 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $87.44 | - | 2 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $32.32 | +48.51% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $18 | $21.95 | -18.00% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4.5 | $0.6503 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $38 | $6.52 | n/a | 5 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3.25 | $2.93 | n/a | 15 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $53 | $69.64 | n/a | 27 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4.75 → $4.25 | $6.72 | n/a | 15 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $1.26 | n/a | 16 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.5 → $6 | $3.82 | n/a | 37 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $45 | $14.93 | n/a | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 → $38 | $52.10 | n/a | 11 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $105 → $110 | $127.23 | n/a | 20 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 → $3 | $0.7859 | n/a | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 → $15 | $10.03 | n/a | 25 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $19 | $9.09 | n/a | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $19 | $1.16 | n/a | 17 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $1.68 | n/a | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $1.51 | n/a | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 | $1.49 | n/a | 8 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $1.75 | $4.17 | n/a | 9 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $1.41 | n/a | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $8.94 | n/a | 39 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 → $26 | $31.35 | n/a | 24 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $1.75 | $2.22 | n/a | 8 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 → $1.75 | $1.99 | n/a | 4 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $29.35 | n/a | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $1.35 | n/a | 3 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $4 | $14.53 | n/a | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 → $36 | $12.22 | n/a | 4 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $17 | $1.79 | n/a | 7 | Aug 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $18 | $2.35 | n/a | 4 | Apr 7, 2020 |
Tango Therapeutics
Jun 8, 2026
Reiterated: Buy
Price Target: $30 → $36
Current: $32.16
Upside: +11.94%
Q32 Bio
May 22, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $12.75
Upside: +9.80%
Avalo Therapeutics
May 14, 2026
Maintained: Buy
Price Target: $39 → $45
Current: $14.33
Upside: +214.03%
Upstream Bio
May 14, 2026
Maintained: Buy
Price Target: $51 → $50
Current: $5.92
Upside: +744.59%
Erasca
May 12, 2026
Maintained: Buy
Price Target: $28 → $26
Current: $13.38
Upside: +94.32%
Sutro Biopharma
Apr 30, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $28.17
Upside: +77.49%
Revolution Medicines
Apr 24, 2026
Maintained: Buy
Price Target: $140 → $185
Current: $156.58
Upside: +18.15%
Climb Bio
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $10.71
Upside: +68.07%
Spyre Therapeutics
Apr 14, 2026
Maintained: Buy
Price Target: $53 → $84
Current: $83.41
Upside: +0.71%
Apogee Therapeutics
Mar 30, 2026
Maintained: Buy
Price Target: $105 → $110
Current: $85.24
Upside: +29.05%
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $26
Current: $9.07
Upside: +186.66%
Jan 29, 2026
Maintained: Buy
Price Target: $30
Current: $17.07
Upside: +75.75%
Jan 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $87.44
Upside: -
Jan 9, 2026
Reiterated: Buy
Price Target: $48
Current: $32.32
Upside: +48.51%
Dec 18, 2025
Initiated Coverage: Hold
Price Target: $18
Current: $21.95
Upside: -18.00%
Mar 21, 2025
Maintained: Buy
Price Target: $4.5
Current: $0.6503
Upside: n/a
Mar 20, 2025
Maintained: Buy
Price Target: $36 → $38
Current: $6.52
Upside: n/a
Mar 7, 2025
Maintained: Buy
Price Target: $3.25
Current: $2.93
Upside: n/a
Mar 6, 2025
Maintained: Hold
Price Target: $53
Current: $69.64
Upside: n/a
Mar 3, 2025
Maintained: Hold
Price Target: $4.75 → $4.25
Current: $6.72
Upside: n/a
Feb 28, 2025
Maintained: Buy
Price Target: $10
Current: $1.26
Upside: n/a
Feb 28, 2025
Maintained: Hold
Price Target: $7.5 → $6
Current: $3.82
Upside: n/a
Feb 27, 2025
Maintained: Buy
Price Target: $50 → $45
Current: $14.93
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $37 → $38
Current: $52.10
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $105 → $110
Current: $127.23
Upside: n/a
Jan 29, 2025
Rated: Buy
Price Target: $15 → $3
Current: $0.7859
Upside: n/a
Jan 17, 2025
Maintained: Buy
Price Target: $40 → $15
Current: $10.03
Upside: n/a
Nov 6, 2024
Rated: Buy
Price Target: $19
Current: $9.09
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: $10 → $19
Current: $1.16
Upside: n/a
Oct 8, 2024
Rated: Buy
Price Target: $15
Current: $1.68
Upside: n/a
Sep 16, 2024
Reiterated: Buy
Price Target: $10 → $8
Current: $1.51
Upside: n/a
Sep 16, 2024
Rated: Buy
Price Target: $30
Current: $1.49
Upside: n/a
Aug 27, 2024
Downgraded: Hold
Price Target: $5 → $1.75
Current: $4.17
Upside: n/a
Apr 22, 2024
Initiated Coverage: Buy
Price Target: $20
Current: $1.41
Upside: n/a
Apr 8, 2024
Maintained: Buy
Price Target: $15
Current: $8.94
Upside: n/a
Mar 14, 2024
Rated: Buy
Price Target: $25 → $26
Current: $31.35
Upside: n/a
May 23, 2023
Downgraded: Hold
Price Target: $15 → $1.75
Current: $2.22
Upside: n/a
Sep 14, 2022
Maintained: Hold
Price Target: $1.5 → $1.75
Current: $1.99
Upside: n/a
May 31, 2022
Maintained: Buy
Price Target: $6
Current: $29.35
Upside: n/a
May 31, 2022
Maintained: Buy
Price Target: $15
Current: $1.35
Upside: n/a
May 12, 2022
Maintained: Buy
Price Target: $10 → $4
Current: $14.53
Upside: n/a
Mar 9, 2022
Maintained: Buy
Price Target: $45 → $36
Current: $12.22
Upside: n/a
Aug 21, 2020
Maintained: Buy
Price Target: $15 → $17
Current: $1.79
Upside: n/a
Apr 7, 2020
Maintained: Buy
Price Target: $28 → $18
Current: $2.35
Upside: n/a